ES2134797T3 - Peptidos y fragmentos de peptidos terapeuticamente utiles. - Google Patents
Peptidos y fragmentos de peptidos terapeuticamente utiles.Info
- Publication number
- ES2134797T3 ES2134797T3 ES92905196T ES92905196T ES2134797T3 ES 2134797 T3 ES2134797 T3 ES 2134797T3 ES 92905196 T ES92905196 T ES 92905196T ES 92905196 T ES92905196 T ES 92905196T ES 2134797 T3 ES2134797 T3 ES 2134797T3
- Authority
- ES
- Spain
- Prior art keywords
- peptides
- fragments
- therapeutically useful
- oncogen
- presented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 239000012634 fragment Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 238000009566 cancer vaccine Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
SE PRESENTAN PEPTIDOS SINTETICOS Y FRAGMENTOS DE PRODUCTOS DE LA PROTEINA DEL ONCOGEN QUE PRODUCEN LA INMUNIDAD CELULAR T, PARA SU USO EN VACUNAS CONTRA EL CANCER Y COMPUESTOS PARA EL TRATAMIENTO DEL CANCER.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB919103974A GB9103974D0 (en) | 1991-02-26 | 1991-02-26 | Therapeutically useful peptides or peptide fragments |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2134797T3 true ES2134797T3 (es) | 1999-10-16 |
Family
ID=10690575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES92905196T Expired - Lifetime ES2134797T3 (es) | 1991-02-26 | 1992-02-21 | Peptidos y fragmentos de peptidos terapeuticamente utiles. |
Country Status (14)
Country | Link |
---|---|
US (1) | US5961978A (es) |
EP (1) | EP0529023B1 (es) |
AT (1) | ATE181337T1 (es) |
AU (1) | AU660452B2 (es) |
CA (1) | CA2077537C (es) |
DE (1) | DE69229428T2 (es) |
DK (1) | DK0529023T3 (es) |
ES (1) | ES2134797T3 (es) |
FI (1) | FI108139B (es) |
GB (2) | GB9103974D0 (es) |
GR (1) | GR3031234T3 (es) |
HK (1) | HK1011370A1 (es) |
NO (1) | NO923953L (es) |
WO (1) | WO1992014756A1 (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2124595A1 (en) * | 1992-09-30 | 1994-04-14 | Hanswalter Zentgraf | Process for detecting p53-specific antibodies |
AU6363094A (en) * | 1993-03-15 | 1994-10-11 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Peptide coated dendritic cells as immunogens |
AT399656B (de) * | 1993-03-19 | 1995-06-26 | Boehringer Ingelheim Int | Verfahren zur herstellung von krebsvakzinen |
GB9422814D0 (en) * | 1994-11-11 | 1995-01-04 | Medinnova Sf | Chemical method |
US6156316A (en) * | 1995-05-08 | 2000-12-05 | Sloan-Kettering Institute For Cancer Research | Oncogene fusion protein peptide vaccines |
US6365151B1 (en) | 1996-01-19 | 2002-04-02 | Philadelphia Health And Educational Corporation | Cellular immunogens comprising cognate proto-oxogenes |
US7709002B1 (en) * | 1996-04-19 | 2010-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes |
EP0895538B1 (en) | 1996-04-19 | 2002-07-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Mutated ras peptides for generation of cd8+ cytotoxic t lymphocytes |
US6069229A (en) * | 1997-03-07 | 2000-05-30 | Schering Corporation | Mammalian proteinases; oxidoreductases; related reagents |
GB2328689A (en) * | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
NO314086B1 (no) | 1998-05-08 | 2003-01-27 | Gemvax As | Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til |
NO315238B1 (no) | 1998-05-08 | 2003-08-04 | Gemvax As | Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy |
US7030211B1 (en) * | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
NO309798B1 (no) * | 1999-04-30 | 2001-04-02 | Targovax As | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen |
US7700359B2 (en) * | 2000-06-02 | 2010-04-20 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells |
GB0031430D0 (en) | 2000-12-22 | 2001-02-07 | Norsk Hydro As | Polypeptides |
GB0105238D0 (en) * | 2001-03-02 | 2001-04-18 | Norsk Hydro As | Vaccines |
JP4376629B2 (ja) * | 2002-01-08 | 2009-12-02 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 癌性胸部細胞において差次的に発現された遺伝子産物およびその使用方法 |
US20030206916A1 (en) * | 2002-05-03 | 2003-11-06 | Rush-Presbyterian-St. Luke's Medical Center | Immunogenic peptides |
ES2676503T3 (es) * | 2002-12-16 | 2018-07-20 | Globeimmune, Inc. | Vacunas basadas en levadura como inmunoterapia |
US8343502B2 (en) | 2002-12-16 | 2013-01-01 | Globeimmune, Inc. | Yeast-based vaccines as immunotherapy |
US7439042B2 (en) * | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
EP2460533A3 (en) | 2004-10-18 | 2014-01-08 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
US9732131B2 (en) | 2006-02-27 | 2017-08-15 | Calviri, Inc. | Identification and use of novopeptides for the treatment of cancer |
US7745128B2 (en) * | 2006-03-27 | 2010-06-29 | Globeimmune, Inc. | Ras mutation and compositions and methods related thereto |
US20080079547A1 (en) * | 2006-09-29 | 2008-04-03 | Sensormatic Electronics Corporation | Radio frequency identification reader having a signal canceller and method thereof |
JP2012503011A (ja) | 2008-09-19 | 2012-02-02 | グローブイミューン,インコーポレイテッド | 慢性c型肝炎ウイルス感染の免疫療法 |
GB0821616D0 (en) | 2008-11-26 | 2008-12-31 | Lytix Biopharma As | Compounds |
EP3369432A1 (en) | 2013-12-09 | 2018-09-05 | Targovax Asa | A peptide mixture |
JP2017514847A (ja) * | 2014-05-06 | 2017-06-08 | タルゴバックス エーエスエー | 突然変異rasペプチド及び化学療法剤を含むペプチドワクチン |
BR112019015797A2 (pt) | 2017-02-01 | 2020-03-17 | Modernatx, Inc. | Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação |
WO2018145020A1 (en) * | 2017-02-03 | 2018-08-09 | The Medical College Of Wisconsin, Inc. | Kras peptide vaccine compositions and method of use |
CA3065325A1 (en) | 2017-06-02 | 2018-12-06 | Arizona Board Of Regents On Behalf Of Arizona State University | A method to create personalized cancer vaccines |
WO2019055618A1 (en) | 2017-09-15 | 2019-03-21 | Arizona Board Of Regents On Behalf Of Arizona State University | METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY |
SG11202008433QA (en) * | 2018-03-02 | 2020-09-29 | Elicio Therapeutics Inc | Compounds including a mutant kras sequence and a lipid and uses thereof |
CN114573688A (zh) * | 2018-10-19 | 2022-06-03 | 杭州纽安津生物科技有限公司 | 通用性多肽疫苗及其在制备治疗/预防胰腺癌药物中的应用 |
EP4038222A4 (en) | 2019-10-02 | 2023-10-18 | Arizona Board of Regents on behalf of Arizona State University | METHODS AND COMPOSITIONS FOR IDENTIFYING NEOANTIGENS FOR USE IN THE TREATMENT AND PREVENTION OF CANCER |
US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1252046A (en) * | 1982-11-04 | 1989-04-04 | Martin J. Cline | Methods for oncogenic detection |
CA1219232A (en) * | 1983-08-17 | 1987-03-17 | Richard A. Lerner | Polypeptide-induced monoclonal receptors to protein ligands |
CA1296660C (en) * | 1985-01-29 | 1992-03-03 | Walter P. Carney | Monoclonal antibody against a ras oncogene p21 related dodecapeptide |
US4898932A (en) * | 1985-01-29 | 1990-02-06 | E. I. Du Pont De Nemours And Company | Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins |
US5100664A (en) * | 1985-09-20 | 1992-03-31 | Cetus Corporation | Human IL-2 as a vaccine adjuvant |
DK354487A (da) * | 1986-07-11 | 1988-01-12 | Noboru Yanaihara | Oncogen-relaterede peptider |
CA1339069C (en) * | 1987-11-09 | 1997-07-29 | Henry Lee Niman | Polypeptide-induced monoclonal receptors to protein ligand |
US4957859A (en) * | 1988-02-16 | 1990-09-18 | Hoffmann-La Roche Inc. | Antibodies for transforming ras protein |
EP0370012A1 (en) * | 1988-03-08 | 1990-05-30 | E.I. Du Pont De Nemours And Company | Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins |
EP0411018B1 (en) * | 1988-04-22 | 1997-06-04 | Oncogene Science, Inc. | Detection, quantitation and classification of ras proteins in body fluids and tissues |
EP0354808B1 (en) * | 1988-08-12 | 1997-12-03 | Ligand Pharmaceuticals Incorporated | Polypeptide-induced monoclonal receptors to protein ligands |
ES2070492T3 (es) * | 1990-01-26 | 1995-06-01 | Washington Res Found | Reactividad inmunitaria para oncogenes expresados activos para diagnostico y tratamiento de estados malignos. |
-
1991
- 1991-02-26 GB GB919103974A patent/GB9103974D0/en active Pending
-
1992
- 1992-02-21 WO PCT/NO1992/000032 patent/WO1992014756A1/en active IP Right Grant
- 1992-02-21 EP EP92905196A patent/EP0529023B1/en not_active Expired - Lifetime
- 1992-02-21 AU AU12729/92A patent/AU660452B2/en not_active Ceased
- 1992-02-21 CA CA002077537A patent/CA2077537C/en not_active Expired - Lifetime
- 1992-02-21 DK DK92905196T patent/DK0529023T3/da active
- 1992-02-21 ES ES92905196T patent/ES2134797T3/es not_active Expired - Lifetime
- 1992-02-21 DE DE69229428T patent/DE69229428T2/de not_active Expired - Lifetime
- 1992-02-21 AT AT92905196T patent/ATE181337T1/de not_active IP Right Cessation
- 1992-02-26 GB GB9204098A patent/GB2253211A/en not_active Withdrawn
- 1992-09-11 FI FI924069A patent/FI108139B/fi active
- 1992-10-12 NO NO92923953A patent/NO923953L/no unknown
-
1995
- 1995-05-03 US US08/433,133 patent/US5961978A/en not_active Expired - Lifetime
-
1998
- 1998-11-30 HK HK98112448A patent/HK1011370A1/xx not_active IP Right Cessation
-
1999
- 1999-09-16 GR GR990402325T patent/GR3031234T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
NO923953L (no) | 1993-03-26 |
NO923953D0 (no) | 1992-10-12 |
DE69229428D1 (de) | 1999-07-22 |
CA2077537C (en) | 2000-06-13 |
ATE181337T1 (de) | 1999-07-15 |
FI924069A0 (fi) | 1992-09-11 |
GB2253211A (en) | 1992-09-02 |
FI108139B (fi) | 2001-11-30 |
WO1992014756A1 (en) | 1992-09-03 |
AU1272992A (en) | 1992-09-15 |
FI924069A (fi) | 1992-09-11 |
GR3031234T3 (en) | 1999-12-31 |
EP0529023A1 (en) | 1993-03-03 |
DK0529023T3 (da) | 2000-01-17 |
HK1011370A1 (en) | 1999-07-09 |
AU660452B2 (en) | 1995-06-29 |
CA2077537A1 (en) | 1992-08-27 |
US5961978A (en) | 1999-10-05 |
GB9204098D0 (en) | 1992-04-08 |
DE69229428T2 (de) | 2000-06-29 |
GB9103974D0 (en) | 1991-04-10 |
EP0529023B1 (en) | 1999-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2134797T3 (es) | Peptidos y fragmentos de peptidos terapeuticamente utiles. | |
ES2063515T3 (es) | Ifn-alfa o-glucosilados. | |
GB2255093A (en) | Hiv-1 core protein fragments | |
ES2196024T3 (es) | Vacunas conjugadas de gangliosido-klh con qs-21. | |
CY1105963T1 (el) | Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης | |
ES2060310T3 (es) | Utilizacion de la n-miristoil-(s)-fenilalanina para la obtencion de medicamentos destinados al tratamiento de enfermedades que hacen intervenir la miristoilacion. | |
AR023806A1 (es) | Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas | |
BR9814473A (pt) | Imunógenos anti-retrovirais, preparação e uso | |
ES2153665T3 (es) | Usos terapeuticos de productos proteicos bactericidas/incrementadores de la permeabilidad (bpi) para la meningococemia humana. | |
ES2194836T3 (es) | Peptidos para su uso en vacunacion e induccion de anticuerpos neutralizantes contra el virus de la inmunodeficiencia humana. | |
EP0511306A4 (en) | Tumor killing effects of enterotoxins and related compounds | |
ATE212540T1 (de) | Antitumorvakzine | |
ATE193974T1 (de) | Chlamydia impfstoffen | |
NO179855C (no) | Fremgangsmåte for fremstilling av et legemiddel | |
UA42741C2 (uk) | Пептид маститної вакцини (варіанти), пептид складного антигенного представлення (варіанти), фармацевтична композиція (варіанти) | |
DE59610098D1 (de) | Protein mit anti-tumorwirkung | |
ES2185083T3 (es) | Proteina estimulante de macrofagos para el tratamiento de patologias del sistema nervioso. | |
DK0427633T3 (da) | Anvendelse af et polypeptid med gammainterferonaktivitet til fremstilling af farmaceutiske præparater beregnet til behandling af primitiv pleuracancer | |
NO20000976L (no) | Peptider | |
GT199500023A (es) | Formas de dosificacion de liberacion controlada azitromicina | |
ITRM920091A1 (it) | Uso di derivati del trenbolone per la terapia dello stress in acquacoltura. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 529023 Country of ref document: ES |